Correspondence 0001493152-23-027649 from BIOXYTRAN, INC (BIXT) (CIK 0001445815) (BIXT)
BIOXYTRAN, INC (BIXT) (CIK 0001445815)
Date: Aug. 10, 2023 · CIK: 0001445815 · Accession: 0001493152-23-027649
AI Filing Summary & Sentiment
File numbers found in text: 333-272691
Letter
Re:
August 10, 2023
Attn: Tyler Howes
United States Securities and Exchange Commission
Division of Corporation Finance Office of Life Sciences
F Street, NE
Washington, D.C. 20549
Bioxytran, Inc.
Amendment No. 5 to Registration Statement on Form S-1
File No. 333-272691
Filed August 9, 2023
Ladies and Gentlemen:
Please consider this as our request to accelerate the effective date of the above-referenced registration statement for Bioxytran, Inc. (the “Company”). We request that the registration statement be made effective as of August 14, 2023, at 5:00 p.m. EST, or as soon thereafter as possible.
The Company acknowledges that should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing.
The Company acknowledges that the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
The Company acknowledges that it may to assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any further questions, please do not hesitate to contact the undersigned.
Sincerely,
BIOXYTRAN,
INC.
Show Raw Text
CORRESP
1
filename1.htm
August
10, 2023
Attn:
Tyler Howes
United
States Securities and Exchange Commission
Division
of Corporation Finance Office of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Re:
Bioxytran,
Inc.
Amendment
No. 5 to Registration Statement on Form S-1
File
No. 333-272691
Filed
August 9, 2023
Ladies
and Gentlemen:
Please
consider this as our request to accelerate the effective date of the above-referenced registration statement for Bioxytran, Inc. (the
“Company”). We request that the registration statement be made effective as of August 14, 2023, at 5:00 p.m. EST, or as soon
thereafter as possible.
The
Company acknowledges that should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it
does not foreclose the Commission from taking any action with respect to the filing.
The
Company acknowledges that the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing
effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
The
Company acknowledges that it may to assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.
If
you have any further questions, please do not hesitate to contact the undersigned.
Sincerely,
BIOXYTRAN,
INC.
/s/
David Platt
David
Platt, PhD
Chief
Executive Officer